Report: Chinese biopharma Jiangsu Hansoh eyes a $3B IPO

Jiangsu Hansoh Pharmaceutical, a Chinese drug developer, is moving toward a Hong Kong IPO worth up to $3 billion, according to Dow Jones. The company, which has operations in China and the U.S., develops and manufactures treatments for cancer, infectious disease, diabetes and cardiovascular ailments, according to its website. Jiangsu Hansoh has reached out to a group of U.S. banks to put together its initial offering, Dow Jones reports, planing to float shares in the third quarter of this year. News

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.